Luana sells ARWR 5.8: This dramatic spike in Arrowhead's share price was triggered by a positive clinical update from the company for its experimental hepatitis B treatment, ARC-520, that is currently being studied in an ongoing mid-stage trial.

Gilead's first human data on its drug is expected by year-end. It's bumped along below 10 ever since. We are optimistic that this will ultimately translate into powerful clinical outcomes for ARC-520 and follow-on candidates against multiple indications. We have achieved the highest knockdown ever reported in humans with RNAi and a safety profile that continues to be excellent. The company is leveraging its proprietary Dynamic Polyconjugate delivery platform to develop targeted drugs based on the RNA interference mechanism that efficiently silences disease-causing genes.


Johanna:
ARC-520 induces deep HBsAg reduction in chronically HBV infected chimps and one of four HBeAg-positive chimps demonstrated signs of immune reactivation during therapy.

Beulah:
Arrowhead identifies a large target HBV population for ARC-520 and describes a new paradigm for the HBV lifecycle.

Ulrike:
Also, Arrowhead will discuss findings from an ARC-520 study with a background therapy of nucleotide/nucleoside analog inhibitors (NUCs) tenofovir and/or entecavir.

Tish:
This event was set up to discuss top-line findings from the Heparc-2001 Phase 2a clinical study of ARC-520, its candidate for the treatment of chronic hepatitis B infection.

John:
The company is hosting the event Thursday in New York, with its presentation starting at 11:00 a.m.

Aleen:
DYNAMIC POLYCONJUGATES is a trademark of Arrowhead Research Corporation.

Nichelle:
Cellceutix ( OTCPK:CTIX ) shares closed 3.28% lower.

Roni:
The stock closed 1.15% lower on volume of 1.40 million.

Tierra:
Organovo Holdings (NYSEMKT: ONVO ) shares ended the day 8.79% lower.

Elana:
Hemispherx BioPharma (NYSEMKT: HEB ) shares also saw significant activity.

Arrowhead Research Corp. (NASDAQ:ARWR)
//stockhand.net/us/?q=nasdaq%3Aarwr&id=596910